We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform. FORTY51 Ventures is the first institutional investor in your biotech company.
First or Best in Class
We bring decades of experience in the pharma industry and support entrepreneurs in their journey of venture creation.
We are therapeutic area agnostic with a preference for CNS, oncology, immunology and inflammation, fibrotic disorders and optha.
FORTY51 Ventures was founded in April 2022 as company builder and early stage investor of exceptional biotech companies in
Europe with first or best-in-class potential. We source and incubate locally, and mature companies globally.
Our vast and deep experience allows us to support entrepreneurs and be involved hands-on to build stronger companies faster.
Let's Get To Know One Another
Together with you we build stronger companies. We look forward to receiving your message and meet you in 4051 Basel
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.